Abeprazan, 钾转运 ATP 酶抑制剂

阿贝拉赞

Abeprazan

A655268-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H + , K + - ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases. In Vitro The mechanism of action of Abeprazan is reversibly binding to H + , K + ‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Abeprazan inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Abeprazan (DWP14012) 是一种钾竞争性酸阻断剂。Abeprazan 通过可逆的钾竞争性离子结合抑制 H + , K + - ATPase，无需酸激活。Abeprazan 是作为质子泵抑制剂的潜在替代药物而开发的。

1902954-60-2(DMSO)

C19H17F3N2O3S

410.41 g/mol

CNCC1=CN(C(=C1OC)C2=C(C=C(C=C2)F)F)S(=O)(=O)C3=CC=CC(=C3)F

抑制剂

钾转运 ATP 酶抑制剂